PAIN TRIGGERS
Dexamphetamine causes insomnia.
Methylphenidate IR causes flat mood.
SaaS· ADHD patients on stimulant medicationPain 7.00/10WTP 6.0/10Market 8.0/10Validation 7.0Confidence 72%May 13, 2026
StimCombo: Side-Effect Optimized ADHD Stimulant Regimen Tracker
Single stimulant medications force ADHD patients to trade focus benefits for severe side effects like insomnia (Dex) or flat mood (MPH), while safe combination regimens are uncommon, surprising, and poorly tracked.
adhdhealthcaremedication-managementmental-healthmobile-apppersonalized-healthproductivitysaastrackingwellness
1
STAGE 01 · PROBLEM
Is the problem real?
CANONICAL PROBLEM
ADHD stimulant medications cause significant side effects like insomnia or flat mood, making single-drug regimens suboptimal.
FREQUENCY
Limited repetition signal.
INTENSITY
Users explicitly describe existing tools as bloated/overkill and mention workaround behavior.
EVIDENCE
Dex & MPH in combination
ADHD15
Never heard of someone combining 2 types of stimulant.
commentNever heard of someone combining 2 types of stimulant. Why won't he give you something like vyvanse instead?
2
STAGE 02 · CUSTOMER
Who feels this pain?
TARGET USERS
ADHD patients on stimulant medicationAdult A D H D Medication Experimenters
ADHD adults prescribed Dexamphetamine or Methylphenidate who cycle or combine stimulants to balance focus benefits against insomnia and emotional flatness.
Context
Find an effective ADHD medication combination or alternative that provides focus benefits without insomnia or emotional flattening.
Switching between Dex and MPH to manage specific side effects.
Considering combining morning Dex with afternoon MPH boosters as suggested by psychiatrist.
Current Workarounds
Switching between Dex and MPH daily or per symptom
Trial-and-error self-adjustment based on psychiatrist advice
Tracking symptoms manually in notes or spreadsheets
3
STAGE 03 · MARKET
Where's the gap?
EXISTING SOLUTION GAPS
Single stimulant medications (Dex or MPH) trade one side effect for another.
Psychiatrist suggestion of Dex + MPH combo is surprising and uncommon per commenter.
OPPORTUNITY & VALUE
Why Now
Multiple users report trading insomnia for flat mood across single stimulants; combo approach mentioned as novel but promising.
Value Proposition
Purpose-built for stimulant combination experiments with psychiatrist-shareable logs, unlike generic mood trackers or single-med reminder apps.
Product Direction
A mobile/web app that lets users log daily stimulant doses (single or combined), side effects, focus levels, and sleep/mood metrics, with guided protocols for testing Dex+MPH combos and sharing structured reports with psychiatrists.
4
STAGE 04 · BUSINESS
How does it make money?
MONETIZATION
$12/moIndividual user plan with unlimited logging
Model
SaaS subscription
WILLINGNESS TO PAY
Users already invest time and emotional energy switching meds or following surprising psych suggestions; they would pay for structured tracking that reduces trial-and-error frustration and helps secure better prescriptions, as evidenced by detailed personal experimentation reports.
5
STAGE 05 · EXECUTION
How do you ship it?
MVP PLAN
“Balance focus and sleep by safely testing stimulant combinations in 4 weeks.”
A mobile/web app that lets users log daily stimulant doses (single or combined), side effects, focus levels, and sleep/mood metrics, with guided protocols for testing Dex+MPH combos and sharing structured reports with psychiatrists.
Core Features
Daily logging of dose type, timing, and combo (Dex morning + MPH afternoon)
Symptom tracker for insomnia, mood, focus with simple scales
Basic combo protocol templates and side-effect correlation charts
PDF export for psychiatrist visits
Weekly Roadmap
1
W1-W2
Core logging system for single and combo doses operational.
- •Build dose entry form supporting Dex/MPH combos
- •Implement basic symptom rating scales
- •Set up local data storage
2
W3-W4
Correlation charts and psychiatrist export complete.
- •Create daily/weekly side-effect vs dose visualizations
- •Generate PDF summary reports
- •Add combo protocol template library
3
W5
Internal testing and beta with 8-10 ADHD users.
- •Recruit beta users from Reddit ADHD communities
- •Polish UI and fix logging bugs
- •Validate export readability with mock psychiatrist feedback
4
W6
Public launch with first 50 signups and initial subscriptions.
- •Deploy Stripe billing
- •Post MVP in r/ADHD and r/adhdwomen
- •Implement basic analytics for retention
Launch Strategy
Launch in r/ADHD, r/adhdwomen, r/ADHDers via targeted posts and psychiatrist partnership outreach
RISKS & ASSUMPTIONS
Top Risks
Medical regulatory risk
App perceived as giving medical advice could trigger FDA scrutiny or liability for unmonitored combo experiments.
Data accuracy and user error
Self-reported doses and symptoms may be inaccurate, leading to misleading insights or unsafe decisions.
Psychiatrist buy-in
Many doctors may dismiss patient-tracked combo data or be reluctant to prescribe combinations.
Low retention after initial experiments
Users may churn once they find a working regimen or revert to single meds.
6
STAGE 06 · DECISION
Should you build it?
NEED A CLEARER CALL?
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoWhat this score means
This idea scores in the upper-middle range of opportunities surfaced by MonetScope, with a validation sub-score of 7/10 against 3 independently sourced evidence signals. A "promising" rating usually indicates a real pain has been detected and discussed in the open, but the pipeline did not find enough signal to flag it as urgent or high-frequency. These opportunities can still produce excellent businesses — they often correspond to "boring" problems that established players have ignored — but the founder should expect a longer customer-development cycle to confirm willingness to pay.
Why this matters for SaaS founders
It sits at the intersection of "adhd", "healthcare", "medication-management", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
Frequently asked questions
Is "StimCombo: Side-Effect Optimized ADHD Stimulant Regimen Tracker" a real validated startup idea or just an AI-generated suggestion?
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
How recent is the underlying data for adhd?
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
What's the difference between "overall score" and "validation score"?
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.